{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:59:27Z","timestamp":1762865967315},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/ftd.0b013e31825479cc","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T11:42:32Z","timestamp":1336477352000},"page":"345-348","source":"Crossref","is-referenced-by-count":4,"title":["Combined Therapy With Thioridazine Decreases Plasma Levels of Quetiapine in Taiwanese Schizophrenic Patients"],"prefix":"10.1097","volume":"34","author":[{"given":"Shen-Chieh","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mong-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Hsin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-O","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210129","first-page":"CD001944","article-title":". Thioridazine for schizophrenia.","volume":"3","author":"Fenton","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-17-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.180.6.515","article-title":". Thioridazine and sudden unexplained death in psychiatric in-patients.","volume":"180","author":"Reilly","year":"2002","journal-title":"Br J Psychiatry"},{"key":"R3-17-20210129","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes.","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"R4-17-20210129","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1185\/030079904125004510","article-title":"Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.","volume":"20","author":"Buckley","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R5-17-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.schres.2003.06.001","article-title":"Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia.","volume":"66","author":"Buckley","year":"2004","journal-title":"Schizophr Res"},{"key":"R6-17-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R7-17-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/10401239909147064","article-title":"The metabolism of atypical antipsychotic drugs: an update.","volume":"11","author":"Shen","year":"1999","journal-title":"Ann Clin Psychiatry"},{"key":"R8-17-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R9-17-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":". Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.","volume":"131","author":"Daniel","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R10-17-20210129","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","article-title":". Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.","volume":"35","author":"Shen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R11-17-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-200204000-00004","article-title":". The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.","volume":"22","author":"Potkin","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R13-17-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0731-7085(99)00036-9","article-title":"Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection.","volume":"20","author":"Davis","year":"1999","journal-title":"J Pharm Biomed Anal"},{"key":"R14-17-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":". Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R15-17-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":". Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.","volume":"18","author":"Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R16-17-20210129","first-page":"390","article-title":". Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.","volume":"25","author":"Li","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"R17-17-20210129","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31825479cc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:38Z","timestamp":1620952778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201206000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31825479cc","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}